Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company,
today reported positive results from the first of three Phase III studies of
velaglucerase alfa, its enzyme replacement therapy in development fo...
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
FREMONT, Calif., July 16 /PRNewswire/ -- Velos, Inc., the trusted leader in clinical research management systems, announced today the availability of new system capabilities to ensure that the cancer center community can fulfill new registration requirements for the U.S. National Cancer ...
Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference
VIENNA, July 15 /PRNewswire-USNewswire/ -- This week, more than 3,000 leading scientists convened to report and discuss the latest advances in research on treatments, risk factors, diagnosis and causes for the health epidemic of the 21st century -- Alzheimer's disease -- at the Alzheimer's As...
Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline
VIENNA, Austria, July 12 /PRNewswire/ -- Results from two large studies using DHA, an omega 3 fatty acid, were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
VIENNA, Va., July 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM ), a late stage cancer immunotherapy company, announced today that Dr. Eyal Talor, CEL-SCI's Senior Vice President of Research and Manufacturing, has been invited to present to the NIH, NCI's Clinical Cent...
New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases
Bill would remove financial penalties for participating in research studies
BETHESDA, Md., June 15 /PRNewswire-USNewswire/ -- New legislation introduced today would allow patients with rare diseases to participate in clinical drug studies without losing their eligibility for government health...
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
--First of 2 data sets to be released--
PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials
in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...
PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL ), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials
over the last five years, which have involved over 175,000 patie...
Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
SAN FRANCISCO, May 6 /PRNewswire-FirstCall/ -- Medizone (Pink Sheets: MZEI) is pleased to announce the commencement of the first in a series of trials
designed to confirm that the Medizone AsepticSure(TM) Hospital Sterilization System can rapidly eliminate hospital-based bacterial pathogens known ...
Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
JERUSALEM, May 5 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.
(OTC: ORMP) ( http://www.oramed.com ), a developer of oral delivery systems,
announced that Phase 2b clinical trials
will commence this week on 30 Type 2
Diabetic volunteers. The study is intended to evaluate the safety,
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
- Progression-Free Survival Data to be Presented for Phase 2 Colorectal and Prostate Trials
- Company to Hold Investor Event on Sunday, May 31 with Oncology Experts -
SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ) today ann...
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
- With half as many injections, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to Pegasys (peginterferon alfa-2a) -
- Patients receiving 900-mcg Albuferon had comparable rates of serious and...
Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...
Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
Company Expands Overseas TBI Trial
COSTA MESA, Calif., March 19 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received a letter from the FDA that outlines what the agency termed a "path forward" as a basis to resume clin...
Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
- 900-mcg Albuferon (albinterferon alfa-2b) dosed every two weeks met the primary efficacy endpoint of sustained virologic response comparable to peginterferon alfa-2a dosed weekly in patients with genotype 1 chronic hepatitis C -
- Patients receiving 900-mcg Albuferon had comparable rates o...
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
SOUTH SAN FRANCISCO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it will delay
further partnership discussions regarding R788 until after results from the
Phase 2b clinical trials
of R788 are available. The company expects that
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its current financial status, the Board of Directors and management have determined that it is in the best int...
Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
RESEARCH TRIANGLE PARK, N.C., Jan. 26 /PRNewswire/ -- Mardil Inc., a cardiac device company with novel technology for treating mitral valve regurgitation, has successfully advanced its device to first-in-human testing, a milestone achievement for the 2-year-old company.
The first patient was...
Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
PALO ALTO, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals,
Inc. (Nasdaq: JAZZ ) today announced completion of enrollment in the second of
two Phase III pivotal clinical trials
of JZP-6 (sodium oxybate) for the
treatment of fibromyalgia.
"Completion of enrollment in thi...
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials
for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 stu...
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
SKOKIE, Ill., Dec. 2 /PRNewswire/ -- Horizon Therapeutics, Inc., a
privately held biopharmaceutical company, today announced that two pivotal
Phase 3 trials
evaluating its lead investigational product candidate, HZT-501,
met all primary endpoints. HZT-501, a novel, proprietary fixed-dose
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing
human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and
other infectious agents, announced today that the launch of its Phase 2a Human
Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq:
DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM)
(lapuleucel-T), an investigational active cellular immunotherapy, at the
Chemotherapy Foundation Symposium in New York City. The presentation, whi...
Sarah Cannon Research Institute Selects OmniComm Systems' Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
Renowned cancer research center enters into a Technology Transition
agreement with OmniComm to gain more control over the management of their clinical trials
FT. LAUDERDALE, Fla., Nov. 4 /PRNewswire-FirstCall/ -- OmniComm
Systems, Inc. (OTC Bulletin Board: OMCM.OB...
Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) announced today that its drug candidate for metastatic
breast cancer, BZL101, will advance to Phase 2 clinical testing after the
successful completion of a second Phase 1 clinical trial.
The Phase 1B clinical...
Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
JERUSALEM, October 23 /PRNewswire-FirstCall/ --
- An Insulin Suppository Represents an Important Development in the
Treatment of Diabetes as it Provides a Painless Alternative for Effective
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; http://www.oramed.com ), a
First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
Community Leaders/Patients Encouraged to Discuss Challenges; Offer
NEW YORK, Oct. 15 /PRNewswire-USNewswire/ -- On the heels of a major
report revealing that the vast majority of Americans -- and especially
women, older people and racial and ethnic minorities -- are either
Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources
WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 -
EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a
meeting with the U.S. Food ...
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
LYON, France, Oct. 8 /PRNewswire/ -- Vical Incorporated (Nasdaq: VICL )
today is presenting expanded clinical data and new nonclinical data
demonstrating that the company's Vaxfectin(R) adjuvant may be broadly
applicable in DNA- and protein-based infectious disease vaccines and
Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
In a clinical study of adults, VYVANSE taken once-daily significantly
improved the symptoms of ADHD within one week
PHILADELPHIA, Oct. 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, today
announced that a study published in th...
Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
Design Concept of Other Product - Company's Bioabsorbable Stent - Also
Slated for Presentation at Symposium
HONG KONG, Oct. 6 /PRNewswire/ -- Data from multiple clinical trials
the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R
stent, will be presented next week at t...
Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
Study to Assess the Safety and Efficacy of ORMD 0801, Oral Insulin Capsule, on Type 1 Diabetics
JERUSALEM, Israel, September 24 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer
of oral delivery systems, announ...
Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
New Data from Landmark UPLIFT Trial Further Supports Spiriva's Safety
RIDGEFIELD, Conn. and NEW YORK, Sept. 23 /PRNewswire/ -- Boehringer
Ingelheim and Pfizer Inc have released a new analysis of 30 rigorously
controlled clinical trials, including UPLIFT, confirming the long term
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
SINGAPORE, Sept. 18 /PRNewswire/ -- S*BIO Pte Ltd today announced the
initiation of multi-center Phase I clinical trials
of SB1518, a potent and
orally-active JAK2 inhibitor, in patients with leukemia and certain types
of lymphoma. These first Phase I trials
for SB1518 comprise of ascending
Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
Company to Discuss Phase 3 Plans with FDA
PRINCETON, N.J., Sept. 3 /PRNewswire/ -- Agile Therapeutics, Inc.,
announced today that it successfully completed two key clinical trials
the development of the company's new, innovative low-dose, once-weekly,
contraceptive patch, whi...
Clinical Trials Bootcamp Announces Inaugural Meeting
WEST PALM BEACH, Fla., Aug. 14 /PRNewswire/ -- The Clinical Trials
Bootcamp announces its inaugural meeting aimed at educating physicians,
clinical coordinators, clinical research staff and other participants in
clinical trial. It will be held in Boca Raton at the Boca Resort from May
Aon eSolutions Launches Clinical Trials Module
Provides risk managers with comprehensive overview of clinical trials, including exposure and required coverage
CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- Aon eSolutions, the client
technology arm of Aon Corporation (NYSE: AOC ) and the leading provider of
global risk and insu...